Registries, research, and regrets: is the FDA’s post-marketing REMS process not adequately protecting patients?
- 1 November 2011
- journal article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 4 (6) , 339-347
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- New FDA Regulation to Improve Safety Reporting in Clinical TrialsNew England Journal of Medicine, 2011
- Innovation, Regulation, and the FDANew England Journal of Medicine, 2010
- Risk evaluation and mitigation strategies: Impact on patients, health care providers, and health systemsAmerican Journal of Health-System Pharmacy, 2009
- Progressive Multifocal Leukoencephalopathy after Natalizumab MonotherapyNew England Journal of Medicine, 2009
- Reemergence of PML in Natalizumab-Treated Patients — New Cases, Same ConcernsNew England Journal of Medicine, 2009
- Asymptomatic Reactivation of JC Virus in Patients Treated with NatalizumabNew England Journal of Medicine, 2009
- A distributed research network model for post‐marketing safety studies: the Meningococcal Vaccine StudyPharmacoepidemiology and Drug Safety, 2008
- Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatchAmerican Journal of Health-System Pharmacy, 2006
- Introducing MEDWatchJAMA, 1993
- Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problemsJAMA, 1993